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Treatment of infections caused by multidrug-resistant Pseudomonas species is difficult because few antibiotics active
against such organisms are available. Arbekacin, a relatively new aminoglycoside, is effective against Pseudomonas
spp. in vitro. However, no clinical report on arbekacin treatment of a human infection with a multidrug-resistant
Pseudomonas has appeared to date. We encountered a case of pneumonia caused by a Pseudomonas strain
producing a metallo-beta-lactamase; the patient was successfully treated with arbekacin. A 69-year-old male
presented to our hospital experiencing cardiac arrest after rescue from water. Spontaneous circulation had earlier
resumed after brief application of cardiopulmonary resuscitation. The patient was subjected to induced
hypothermia. He experienced severe acute respiratory distress syndrome. The patient regained consciousness on
day 8 post-admission. Episodes of ventilator-associated pneumonia were recorded on days 5 and 12. The causative
organism was a strain of Pseudomonas putida that produced a metallo-beta-lactamase. Combination therapy with
arbekacin and levofloxacin successfully resolved the pneumonia. The patient was transferred to another hospital on
day 37 to undergo further rehabilitation. Strains of P. putida producing metallo-beta-lactamases have become more
widespread in recent years. Colistin is traditionally the drug of last resort to treat infections with multidrug-resistant
Pseudomonas. However, colistin use is associated with a very high frequency of adverse effects, and the costs of
such therapy are not covered by the Japanese health insurance system. Our results indicate that arbekacin is an
efficient alternative to multidrug-resistant Pseudomonas.
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Infections caused by Pseudomonas putida strains that
produce metallo-beta-lactamases (MBLs) are difficult to
treat because effective antibiotics are lacking. Colistin,
the traditional drug of last resort, is not available in Japan,
and the choice of antibiotic treatment for P. putida in-
fections is thus limited. Combination therapy including
arbekacin (ABK), an aminoglycoside antibiotic, has been
reported to be effective against multidrug-resistant
Pseudomonas aeruginosa in vitro [1]. To the best of our
knowledge, no clinical report on ABK treatment of
pneumonia caused by MBL-producing P. putida has yet
appeared. We present a case featuring successful treatment,* Correspondence: iwaci1ta@clin.medic.mie-u.ac.jp
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reproduction in any medium, provided the orusing ABK, of pneumonia caused by MBL-producing
P. putida.Case presentation
A 69-year-old male presented to our hospital post cardiac
arrest. The patient had been in a fishing boat that had ac-
cidentally overturned. The patient was rescued by others
nearby, who called an ambulance. When the paramedics
arrived on scene, his Glasgow Coma Scale was 1-1-1, and
his SpO2 is 76% (10 L/min reservoir mask). Cardiac arrest
occurred in the ambulance. Spontaneous circulation
returned after 2 min of CPR. He was intubated on scene
and was transferred to our hospital by helicopter.
On arrival at our hospital, his vital signs were BP
122/60 mmHg, HR 71 beats/min, and SpO2 93% (SIMV
FiO2 1.0, PEEP 10 cmH2O, peak inspiratory pressure 25l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chest X-ray and CT scan upon ICU admission. Chest radiograph shows diffuse infiltrate bilaterally.
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Metabolic acidosis with lactate elevation was seen.
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Coma Scale score was 1-T-5, and the diameter of his
pupils was 4 mm × 4 mm with light reflex of +/+. Respira-
tory sounds were evident as coarse crackles bilaterally. A
chest X-ray showed diffuse bilateral infiltration (Figure 1).
A chest CT scan revealed infiltrates bilaterally in the
dependent lung regions and left multiple costal frac-
tures with pneumohemothorax, probably attributable
to chest compression. Arterial blood gas revealed the
presence of mixed acidosis with severe hypoxia: pH
7.04, PaO2 52 mmHg, PaCO2 52 mmHg, HCO3 14.1
mmol/L, BE −16.6 mmol/L, and lactate 5.4 mmol/L.
The white blood cell count was slightly elevated to
12,470/μL (Table 1).
The patient was diagnosed as post cardiac arrest due to
severe hypoxia. He was subjected to induced hypothermia
(34°C for 24 h). A chest drainage tube was inserted to treat
the left-side pneumohemothorax. The ventilator setting
was changed to the airway pressure-releasing ventilation
mode; the relevant settings were Phigh 26 cmH2O, Plow 5
cmH2O, Thigh 3.5 s, Tlow 0.5 s, and FiO2 0.6. The ARDS
was treated via nitric oxide inhalation (10 ppm), and the
patient was placed in prone position. Sulbactam-ampicillin
(1.5 g every 6 h) treatment was commenced for prophylaxis
of aspiration pneumonia. The clinical course is shown in
Figure 2. The patient was rewarmed on day 6, at which
time he had fully recovered neurologically.
On day 4, the patient developed late-onset ventilator-
associated pneumonia. We initiated empirical therapy with
tazobactam-piperacillin 4.5 g every 8 h and vancomycin
hydrochloride 1 g every 12 h. The patient experienced
general edema and impairment of renal function, and the
blood concentration of vancomycin hydrochloride was
thus much greater than the predicted value. We, therefore,
replaced this drug with linezolid on day 7. Culture of spu-
tum taken on day 7 revealed the presence of methicillin-
sensitive Staphylococcus aureus. We changed linezolid to
cefazolin on day 11. Although the inflammatory symp-
toms improved slightly, fever and sputum production
became worse on day 12, and we suspected that a secondepisode of ventilator-associated pneumonia had developed.
The patient required tracheostomy on day 13. On day 15,
sputum culture taken on day 12 revealed the presence
of a P. putida strain that produced an MBL (to be of the
integron-encoded type revealed on day 38). The method of
P. putida isolation was semi-quantitative, and the method
of MBL detection was PCR method. Of the antibiotics
Figure 2 Clinical course of the patient. Inflammatory markers, dose, and duration of the antibiotics used are shown.
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(AMK), arbekacin, and minocycline. The minimum in-
hibitory concentration of ABK was 2.0 μg/mL. The
blood concentrations of AMK could not be measured
in our hospital, whereas that of ABK can. We, therefore,
chose to employ this drug in treatment. As reported
above, the blood concentration of vancomycin exceeded
the predicted value when the drug was used in the earlier
treatment. We, therefore, resolved to carefully titrate ABK
levels in the blood. Our final choice of therapy was ABK
300 mg every 24 h with levofloxacin (LVFX) 500 mg every
24 h. We titrated ABK doses to maintain Cpeak values
over 16 μg/mL and Ctrough values less than 2.0 μg/mL.
Inflammatory symptoms had decreased in extent by day
17, but treatment with both drugs was continued up to
day 26. The patient was transferred to another hospital
on day 37 for further rehabilitation.
Discussion
The increasing prevalence of drug-resistant microbes is
a major issue in modern critical care. Infections caused
by MBL-producing P. putida are difficult to treat, espe-
cially in Japan, where health insurance covers the use ofrelatively few antibiotics. Here, we report on a case of
pneumonia caused by MBL-producing P. putida; the
patient was successfully treated with ABK.
P. putida is a fluorescent member of the Pseudomonas
family and causes nosocomial infections, including pneu-
monia, urinary tract infections, neonatal infections, and
adult bacteremia [2,3]. Pneumonia caused by P. putida is
suspected to be associated with high mortality rates when
bacteremia develops [3,4]. Our patient had experienced
cardiac arrest and was subsequently subjected to induced
hypothermia to prevent hypoxic brain injury. Our patient
was, thus, susceptible to opportunistic nosocomial infec-
tions, especially of the lung.
Historically, P. putida has been considered to be an op-
portunistic pathogen of low virulence and has been suscep-
tible to a range of antibiotics [5]. However, in both Japan
and Korea, the isolation frequencies of imipenem-resistant
Pseudomonas spp. (especially P. aeruginosa and P. putida)
are increasing [6]. Most imipenem-resistant P. aeruginosa
strains produce MBLs. In Korea, 8 of 12 (67%) imipenem-
resistant P. putida isolated in 2005 expressed MBLs [6].
The MBL element of P. putida can be horizontally trans-
ferred to P. aeruginosa [7]. To date, eight types of MBLs
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VIM, SPM, SIM, GIM, DIM, AIM, and KHM [8]. The IMP
type was identified in the strain that infected our patient;
this is the most common form of MBL in Japan. MBL
detection was done by PCR method [9].
Colistin is the antibiotic of choice for treating infections
with MBL-producing Pseudomonas spp. [10]. However,
colistin therapy is not supported by Japanese health in-
surance. Arbekacin is a broad-spectrum aminoglycoside
antibiotic, effective in treating infections with a range of
bacteria, from Gram-positive cocci to Gram-negative
bacilli. This antibiotic is indicated for treatment of infec-
tions with methicillin-resistant S. aureus and has been
reported to effectively kill Pseudomonas spp. in vitro.
However, the clinical effectiveness of ABK is not well
known. Use of aminoglycoside antibiotics is associated with
development of renal toxicity; the blood levels of such
drugs must be therapeutically monitored. We initially
prescribed VCM for our patient but found that the blood
concentration thereof was much higher than what was
expected and threatened to compromise renal function.
We, thus, resolved to carefully monitor aminoglycoside
levels in the blood of our patient. Of the drugs to
which the isolate was sensitive, we chose to prescribe
the aminoglycoside ABK rather than AMK because it
was possible to measure ABK blood concentrations
(but not those of AMK) in our institution. ABK is a rela-
tively new drug, and the pharmacokinetics and pharmaco-
dynamics thereof remain not to be fully investigated. The
optimal blood concentration of ABK has not yet been
established. For aminoglycoside drugs, the ratio of peak
blood concentration (Cpeak) to the minimal inhibitory con-
centration has been reported to be related to the clinical
efficacy. Thus, a Cpeak/MIC value greater than 8 was asso-
ciated with a clinical efficacy of over 90% [11]. We there-
fore maintained the Cpeak level of ABK over 16 μg/mL
and the Ctrough level below 2.0 μg/mL. We found that
we could successfully maintain the desired drug blood
concentrations by varying the drug dose.
We choose to additionally prescribe LVFX for two
reasons. First, our patient had not earlier received
any quinolone. Second, P. putida that are resistant to
fluoroquinolones express a drug efflux system [12,13].
We therefore considered that LVFX might nonetheless
be effective if given at high concentrations. However,
later laboratory analysis revealed that the combination
of ABK and LVFX was no more effective against the
isolate in vitro than was ABK alone. Therefore, the ob-
served clinical effect may have been attributable to the
action of ABK alone.
The clinical course of our patient was favorable; no
adverse events were noted. Thus, we propose that com-
bination therapy that includes ABK may effectively treat
infections with MBL-producing Pseudomonas spp.Conclusion
We experienced a case of MBL-producing P. putida suc-
cessfully treated with ABK. ABK is an effective choice of
treatment for MBL-producing Pseudomonas spp.
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